Cochrane · systematic review · CD007470

Vitamin D supplementation for prevention of mortality in adults

Bjelakovic, G, Gluud, LL, Nikolova, D, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library

Metabolic and Endocrine Disorders2 versionsAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 2 · 28.6%Very low 0 · 0%Low 2 · 28.6%Moderate 3 · 42.9%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Show all 2 versions

Vitamin D supplementation for prevention of mortality in adults

Population: adults
7 questions
OutcomeEffectEvidenceStatus / GRADE
All‐cause mortality in trials using vitamin D3 (cholecalciferol) (
RR 0.94 [0.91, 0.98]38 studies · 75927 participantsModerate
Downgraded: risk of bias
Cardiovascular mortality in trials using vitamin D3 (cholecalciferol) (
RR 0.98 [0.9, 1.07]10 studies · 47267 participantsLow
Downgraded: risk of bias, imprecision
Cancer mortality in trials using vitamin D3 (cholecalciferol) (
RR 0.88 [0.78, 0.98]4 studies · 44492 participantsModerate
Downgraded: risk of bias
Adverse events: nephrolithiasis in trials using vitamin D3 combined with calcium (
RR 1.17 [1.02, 1.34]4 studies · 42876 participantsModerate
Downgraded: risk of bias
Adverse events: hypercalcaemia in trials using the active forms of vitamin D (alfacalcidol and calcitriol) (
RR 3.18 [1.17, 8.68]3 studies · 710 participantsLow
Downgraded: risk of bias, imprecision
Health‐related quality of life (
no estimate extracted1 study · 105 participantsUngraded
Health economics (
no estimate extracted1 study · 3270 participantsUngraded